Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
Orserdu (elacestrant)
i
Other names:
RAD1901
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(9)
News
Trials
Company:
DRI Healthcare, Menarini, Radius, SciClone
Drug class:
Selective estrogen receptor degrader
Related drugs:
‹
fulvestrant (57)
SAR439859 (9)
AZD9833 (7)
LY3484356 (7)
OP-1250 (7)
SCR-6852 (4)
GDC-9545 (4)
ZN-c5 (3)
AZD9496 (2)
GDC-0927 (2)
G1T48 (2)
LX-039 (1)
SCR6106 (1)
D-0502 (1)
AND019 (0)
DZD3969 (0)
LSZ102 (0)
SHR9549 (0)
GDC-0810 (0)
EGL-5385-C-1701 (0)
fulvestrant (57)
SAR439859 (9)
AZD9833 (7)
LY3484356 (7)
OP-1250 (7)
SCR-6852 (4)
GDC-9545 (4)
ZN-c5 (3)
AZD9496 (2)
GDC-0927 (2)
G1T48 (2)
LX-039 (1)
SCR6106 (1)
D-0502 (1)
AND019 (0)
DZD3969 (0)
LSZ102 (0)
SHR9549 (0)
GDC-0810 (0)
EGL-5385-C-1701 (0)
›
Associations
(9)
News
Trials
VERI cancer hierarchy
Reset Filters
ER positive + ESR1 mutation
HER2 Negative Breast Cancer
ER positive + ESR1 mutation
HER2 Negative Breast Cancer
elacestrant
Sensitive: A1 - Approval
elacestrant
Sensitive
:
A1
elacestrant
Sensitive: A1 - Approval
elacestrant
Sensitive
:
A1
ESR1 mutation + HR positive
HER2 Negative Breast Cancer
ESR1 mutation + HR positive
HER2 Negative Breast Cancer
elacestrant
Sensitive: A2 - Guideline
elacestrant
Sensitive
:
A2
elacestrant
Sensitive: A2 - Guideline
elacestrant
Sensitive
:
A2
ER positive
HER2 Negative Breast Cancer
ER positive
HER2 Negative Breast Cancer
elacestrant
Sensitive: B - Late Trials
elacestrant
Sensitive
:
B
elacestrant
Sensitive: B - Late Trials
elacestrant
Sensitive
:
B
ER positive
Estrogen Receptor Positive Breast Cancer
ER positive
Estrogen Receptor Positive Breast Cancer
elacestrant
Sensitive: B - Late Trials
elacestrant
Sensitive
:
B
elacestrant
Sensitive: B - Late Trials
elacestrant
Sensitive
:
B
ER mutation
Estrogen Receptor Positive Breast Cancer
ER mutation
Estrogen Receptor Positive Breast Cancer
elacestrant
Sensitive: C2 – Inclusion Criteria
elacestrant
Sensitive
:
C2
elacestrant
Sensitive: C2 – Inclusion Criteria
elacestrant
Sensitive
:
C2
PIK3CA wild-type+ ESR1 wild-type
Breast Cancer
PIK3CA wild-type+ ESR1 wild-type
Breast Cancer
MEN1611 + elacestrant
Sensitive: D – Preclinical
MEN1611 + elacestrant
Sensitive
:
D
MEN1611 + elacestrant
Sensitive: D – Preclinical
MEN1611 + elacestrant
Sensitive
:
D
PIK3CA mutation + ESR1 wild-type
Breast Cancer
PIK3CA mutation + ESR1 wild-type
Breast Cancer
MEN1611 + elacestrant
Sensitive: D – Preclinical
MEN1611 + elacestrant
Sensitive
:
D
MEN1611 + elacestrant
Sensitive: D – Preclinical
MEN1611 + elacestrant
Sensitive
:
D
PIK3CA mutation + ESR1 mutation
Breast Cancer
PIK3CA mutation + ESR1 mutation
Breast Cancer
MEN1611 + elacestrant
Sensitive: D – Preclinical
MEN1611 + elacestrant
Sensitive
:
D
MEN1611 + elacestrant
Sensitive: D – Preclinical
MEN1611 + elacestrant
Sensitive
:
D
ER positive + PIK3CA H1047R
Breast Cancer
ER positive + PIK3CA H1047R
Breast Cancer
elacestrant + OKI-219
Sensitive: D – Preclinical
elacestrant + OKI-219
Sensitive
:
D
elacestrant + OKI-219
Sensitive: D – Preclinical
elacestrant + OKI-219
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login